News

Filter

Current filters:

Ampligen

FDA advisory gives negative opinion on Hemispherx' Ampligen

27-12-2012

The Arthritis Advisory Committee (AAC) of the US Food and Drug Administration last week voted against…

AmpligenBiotechnologyHemispherx BioPharmaImmunologicalsNorth AmericaPharmaceuticalRegulation

FDA gives Hemispherx time to respond to CRL

12-01-2012

Shares of USA-based Hemispherx Biopharma (NYSE Amex: HEB) rose 14% to $0.24 on Wednesday, after the company…

AmpligenHemispherx BioPharmaImmunologicalsNorth AmericaPharmaceuticalRegulation

Back to top